Companies / BOC Sciences / Nimotuzumab
BOC Sciences

Nimotuzumab | BOC Sciences

Nimotuzumab, a humanized IgG1 monoclonal antibody targeting EGFR (KD = 0.21 nM), is directed against the extracellular domain of the EGFR blocking the binding to its ligands. It is a potent antitumor agent that has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC).

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.